SCHEMBL21055841

SCHEMBL21055841

O=C1CCn2c(nc3c[c]ccc3c2=O)N1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.42
ALDH1A1 P00352 7/20 0.42
HSD17B10 Q99714 4/20 0.42
HPGD P15428 3/20 0.42
POLB P06746 2/20 0.40
MAPK10 P53779 1/20 0.39
CYP1A2 P05177 5/20 0.34
CYP1A1 P04798 4/20 0.34
CYP1B1 Q16678 4/20 0.34
PDE5A O76074 3/20 0.34
HDAC6 Q9UBN7 2/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
CYP3A4 P08684 1/20 0.34
PKM P14618 1/20 0.34
TSHR P16473 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
THPO P40225 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22686118 0.75 KDM4E (0.35) KDM4EALDH1A1HSD17B10HPGDPOLB
SCHEMBL32688313 0.71 CRBN (0.44) KDM4EALDH1A1HSD17B10HPGDPOLB
SCHEMBL1713613 0.71 CRBN (0.44) KDM4EALDH1A1HSD17B10HPGDPOLB
SCHEMBL20595719 0.67 CYP1A2 (0.39) ALDH1A1CYP1A2CYP1A1CYP1B1NPC1
SCHEMBL19807936 0.67 SMN1; SMN2 (0.41) KDM4EALDH1A1POLBLMNARAB9A
SCHEMBL11544043 0.65 DAPK3 (0.37) ALDH1A1SMN1; SMN2KMT2AMEN1DDB1
SCHEMBL11550418 0.64 KDM4E (0.40) KDM4EALDH1A1SMN1; SMN2MAPTDDB1
SCHEMBL11549498 0.64 CRBN (0.36) SMN1; SMN2DDB1CRBN
SCHEMBL11545281 0.63 KDM4E (0.41) KDM4EALDH1A1HPGDNPC1RAB9A
SCHEMBL11549394 0.62 SCN9A (0.35) CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369667-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS ANGEX PHARMACEUTICAL, INC. 2020-11-26 US disclosed
EP-3720495-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS Angex Pharmaceutical, Inc. (US) 2020-10-14 EP disclosed
CN-111741964-A Heterocyclic compounds as PRMT5 inhibitors 安杰斯制药公司 2020-10-02 CN disclosed
WO-2019112719-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS ANGEX PHARMACEUTICAL, INC. (US) 2019-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369667-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT6 KDM4E 47/4885ALDH1A1 4188/4885HSD17B10 3271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.